- Home
- RARE vs PLMR Comparison
RARE vs PLMR Comparison
Compare RARE & PLMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | PLMR |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RARE | PLMR |
|---|---|---|
| Price | $33.60 | $123.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | $85.20 | ★ $154.71 |
| AVG Volume (30 Days) | ★ 1.4M | 278.7K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.73 |
| EPS | N/A | ★ 6.40 |
| Revenue | $630,598,000.00 | ★ $778,362,000.00 |
| Revenue This Year | $19.65 | $255.68 |
| Revenue Next Year | $23.65 | $19.34 |
| P/E Ratio | ★ N/A | $19.11 |
| Revenue Growth | 20.63 | ★ 54.59 |
| 52 Week Low | $25.81 | $98.42 |
| 52 Week High | $50.00 | $175.85 |
Technical Indicators
Market Signals| Indicator | RARE | PLMR |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 48.25 |
| Support Level | $32.06 | $121.56 |
| Resistance Level | $34.77 | $126.06 |
| Average True Range (ATR) | 1.40 | 3.52 |
| MACD | 0.08 | -0.77 |
| Stochastic Oscillator | 66.67 | 18.94 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About PLMR Palomar Holdings Inc. Common stock
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. provide insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The companies Earthquake product generate high premium.